Affiliations: [a]
College of Pharmacy, Ajou University, Suwon, Republic of Korea
| [b]
Department of Psychiatry, Ajou University, School of Medicine, Suwon, Republic of Korea
| [c]
Research Institute of Pharmaceutical Sciences and Technology, Ajou University, Suwon, Republic of Korea
| [d]
Center for Gendered Innovations in Science and Technology Research, Seoul, Republic of Korea
| [e]
Department of Food and Nutrition, College of Human Ecology, Seoul National University, Seoul, Republic of Korea
Correspondence:
[*]
Correspondence to: Yi-Sook Jung, PhD, College of Pharmacy, Ajou University, Worldcupro 206, Suwon 16499, Republic of Korea. Tel.: +82 31 219 3444; Fax: +82 31 219 3534; E-mail: yisjung@ajou.ac.kr and Sukhyang Lee, PharmD, College of Pharmacy, Ajou University, Worldcupro 206, Suwon 16499, Republic of Korea. Tel.: +82 31 219 3443; Fax: +82 31 219 3534; E-mail: suklee@ajou.ac.kr.
Note: [1] These two authors contributed equally to this work.
Abstract: Background:Ischemic heart disease (IHD) is associated with cognitive decline and may contribute to an increased risk of dementia. Objective:The goal of the present study was to investigate whether cilostazol use is associated with a lower risk of incident dementia in Asian patients with IHD, and whether these effects differed based on sex. Methods:This retrospective cohort study was performed using the Korean National Insurance Claim Data of the Health Insurance Review and Assessment Service; the duration of the study was from January 1, 2007 to December 31, 2015. The study group comprised 66,225 patients with IHD, aged >65 years, who had received cilostazol. Age- and sex-matched IHD patients without cilostazol exposure were selected as the control group. The risk of dementia was compared between the cilostazol and control groups. Results:Compared to the control group, total cilostazol users had a marginally significant lower risk of incident dementia. After stratification by sex, the reducing effect of cilostazol on incident dementia was significant in female participants, but not in male participants. Female patients who had cilostazol for over 2 years showed a clinically meaningful preventive effect (HR, 0.85; 95% CI, 0.82–0.88). Conclusions:This study suggested that cilostazol treatment may reduce the risk of incident dementia in Korean patients with IHD. Its beneficial effect was remarkably significant in female patients who received cilostazol for over a 2-year period.
Keywords: Cilostazol, dementia, ischemic heart disease, sex difference
